Innoviva Inc (INVA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Innoviva Inc (INVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10142
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innoviva Inc (Innoviva) develops and commercializes small molecule medicines. It focuses on products for various respiratory disorders. The company partners with GSK for the commercialization and development of all its products. It receives royalty payments for its collaboration with GSK. Innoviva is headquartered in Brisbane, California, the US.

Innoviva Inc (INVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innoviva Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Innoviva Inc, Medical Devices Deals, 2012 to YTD 2018 9
Innoviva Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Innoviva Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Theravance and Alfa Wassermann Exercise of Options to Co-Develop For Velusetrag 11
Licensing Agreements 12
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 12
Theravance Enters Into Licensing Agreement With R-Pharm For TD-1792 And Telavancin 14
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 15
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 16
Equity Offering 17
Theravance Completes Private Placement Of Shares For US$213 Million 17
Debt Offering 18
Innoviva Raises USD192.5 Million in Private Placement of Convertible Notes Due 2025 18
Innoviva Raises USD450 Million in Private Placement of 9% Notes Due 2029 19
Theravance Completes Public Offering Of Notes Due 2023 For US$287.5 Million 20
Innoviva Inc – Key Competitors 21
Innoviva Inc – Key Employees 22
Innoviva Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Jul 25, 2018: Innoviva Reports Second Quarter 2018 Financial Results 24
Apr 26, 2018: Innoviva Reports First Quarter 2018 Financial Results 25
Feb 08, 2018: Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results 26
Oct 25, 2017: Innoviva Reports Third Quarter 2017 Financial Results and Provides Business Updates 28
Jul 26, 2017: Innoviva Reports Strong Second Quarter 2017 Financial Results 29
Apr 27, 2017: Innoviva Reports First Quarter 2017 Financial Results 31
Feb 09, 2017: Innoviva Reports Fourth Quarter and Full Year 2016 Financial Results 32
Corporate Communications 34
May 22, 2018: Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer 34
Legal and Regulatory 35
Dec 19, 2017: Innoviva and Sarissa Implement Court Order 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Innoviva Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innoviva Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innoviva Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Innoviva Inc, Medical Devices Deals, 2012 to YTD 2018 9
Innoviva Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Theravance and Alfa Wassermann Exercise of Options to Co-Develop For Velusetrag 11
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 12
Theravance Enters Into Licensing Agreement With R-Pharm For TD-1792 And Telavancin 14
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 15
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 16
Theravance Completes Private Placement Of Shares For US$213 Million 17
Innoviva Raises USD192.5 Million in Private Placement of Convertible Notes Due 2025 18
Innoviva Raises USD450 Million in Private Placement of 9% Notes Due 2029 19
Theravance Completes Public Offering Of Notes Due 2023 For US$287.5 Million 20
Innoviva Inc, Key Competitors 21
Innoviva Inc, Key Employees 22

List of Figures
Innoviva Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innoviva Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Innoviva Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Innoviva Inc (INVA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oman Oil Marketing Co (OOMS):企業の財務・戦略的SWOT分析
    Summary Oman Oil Marketing Co (Oman Oil), a subsidiary of Oman Oil Company SAOC, is an oil and gas company that distributes and markets petroleum products. The company provides products such as lubricants, fuel cards, aviation fuels, commercial fuels and bunkering marine fuels, among others. It offe …
  • Goldman Sachs Private Wealth Management:企業の戦略・SWOT・財務分析
    Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Randox Laboratories Ltd:企業の製品パイプライン分析2018
    Summary Randox Laboratories Ltd (Randox) is a clinical diagnostic company that manufactures and provides clinical diagnostic solutions to laboratories. The company’s products include biochip analyzers, biochip immunoassays, clinical chemistry analyzers and diagnostic reagents among others. It offers …
  • Ascendance Biotechnology Inc-医療機器分野:企業M&A・提携分析
    Summary Ascendance Biotechnology Inc (Ascendance), formerly Hepregen Corp is a healthcare products provider that offers cell based assay products. The company provides vitro micro-liver cell-based platforms for use in safety testing, and pharmaceutical, biotherapeutic and diagnostic product developm …
  • XState Resources Ltd (XST):企業の財務・戦略的SWOT分析
    Summary XState Resources Ltd (XST) is an oil and gas exploration and development company. The company’s business activities include acquisition, exploration, production and development of oil and gas assets. It holds interest in producing gas wells and associated land leases and production and pipel …
  • Diversicare Healthcare Services Inc (DVCR):企業の財務・戦略的SWOT分析
    Summary Diversicare Healthcare Services Inc (Diversicare), formerly Advocat Inc is a healthcare service provider that offers post acute care services and short term rehabilitation and long-term care services to nursing home patients. The company offers services such as life steps rehabilitation prog …
  • Natera Inc (NTRA):企業の製品パイプライン分析
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers Panorama, a non-invasive prenatal screening test that analyzes baby's DNA through a simple blood dra …
  • Eskom Holdings SOC Limited:企業の戦略・SWOT・財務情報
    Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Repligen Corp (RGEN):企業の財務・戦略的SWOT分析
    Summary Repligen Corp (Repligen) operates as a bioprocessing life science company that develops and commercializes consumable products for manufacturing biological drugs. The company's products include Protein A affinity resins, Protein A ligands, ELISA kits, alternating tangential flow system, OPUS …
  • Elavon Inc:企業の戦略・SWOT・財務分析
    Elavon Inc - Strategy, SWOT and Corporate Finance Report Summary Elavon Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Mothercare plc (MTC):企業の財務・戦略的SWOT分析
    Mothercare plc (MTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Chrysaor Holdings Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Chrysaor Holdings Ltd (Chrysaor) is an oil and gas company that offers exploration services. The company develops, explores, produces and commercializes dormant oil and gas discoveries and incremental reserves in the North Sea. It acquires producing fields with associated undeveloped hydroca …
  • CSE Global Limited (544):石油・ガス:M&Aディール及び事業提携情報
    Summary CSE Global Limited (CSE) is a technology company offering process control systems and integrated plant communication systems. It’s process control systems offers emergency shutdown systems, process shutdown systems, integrated control & safety systems and fire and gas detection systems, well …
  • Cardinal Ethanol LLC:企業の戦略的SWOT分析
    Cardinal Ethanol LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • SECI Energia SpA:電力:M&Aディール及び事業提携情報
    Summary SECI Energia SpA (SECI Energia), a subsidiary of SECI SpA is an energy development service provider that operates in the construction, installation and management of renewable energy power plants. The company produces alternative energy through renewable sources. It provides renewable source …
  • SM Energy Company:企業の戦略・SWOT・財務情報
    SM Energy Company - Strategy, SWOT and Corporate Finance Report Summary SM Energy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • St. Augustine Gold and Copper Limited:企業の戦略・SWOT・財務情報
    St. Augustine Gold and Copper Limited - Strategy, SWOT and Corporate Finance Report Summary St. Augustine Gold and Copper Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Zhejiang Jingxin Pharmaceutical Co Ltd (002020):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Jingxin Pharmaceutical Co Ltd (Jingxin Pharma) is a pharmaceutical company that manufactures and markets traditional Chinese medicine. The company provides products such as finished dosage forms, Chinese herbal drugs and APIs. Its finished dosage products comprise simvastatin tablet …
  • NEC Corp (6701):企業の財務・戦略的SWOT分析
    NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Cinnabon LLC:企業の戦略・SWOT・財務情報
    Cinnabon LLC - Strategy, SWOT and Corporate Finance Report Summary Cinnabon LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆